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Abstract: 
Background and Aims: 
We investigated the association between significant liver fibrosis, determined by AST-to-platelet ratio 
index (APRI), and all-cause mortality among HIV-infected patients prescribed antiretroviral therapy 
(ART) in Zambia 
Me hods: Among HIV-infected adults who initiated ART, we categorized baseline APRI scores 
according to established thresholds for significant hepatic fibrosis (APRI ≥1.5) and cirrhosis (APRI 
≥2.0). Using multivariable logistic regression we identified risk factors for elevated APRI including 
demographic characteristics, body mass index (BMI), HIV clinical and immunologic status, and 
tuberculosis. In the subset tested for hepatitis B surface antigen (HBsAg), we investigated the 
association of hepatitis B virus co-infection with APRI score. Using Kaplan-Meier analysis and Cox 
proportional hazards regression we determined the association of elevated APRI with death during 
ART.  
Results: Among 20,308 adults in the analysis cohort, 1,027 (5.1%) had significant liver fibrosis at ART 
initiation including 616 (3.0%) with cirrhosis. Risk factors for significant fibrosis or cirrhosis included 
male sex, BMI <18, WHO clinical stage 3 or 4, CD4+ count <200 cells/mm3, and tuberculosis. Among 
the 237 (1.2%) who were tested, HBsAg-positive patients had four times the odds (adjusted odds ratio, 
4.15; 95% CI, 1.71-10.04) of significant fibrosis compared HBsAg-negatives. Both significant fibrosis 
(adjusted hazard ratio 1.41, 95% CI, 1.21-1.64) and cirrhosis (adjusted hazard ratio 1.57, 95% CI, 1.31-
1.89) were associated with increased all-cause mortality. 
Conclusion: Liver fibrosis may be a risk factor for mortality during ART among HIV-infected individuals 
in Africa. APRI is an inexpensive and potentially useful test for liver fibrosis in resource-constrained 
settings. 
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Key Points: 
• Among 20,308 HIV-infected adults in Lusaka, Zambia, 5.1% had significant liver fibrosis 
(Metavir stage F2-F4) and 3.0% had cirrhosis (Metavir stage F4) determined by AST-to-platelet 
ratio index (APRI) at the time of antiretroviral therapy (ART) initiation. 
• Risk factors for significant fibrosis included male sex, body mass index <18, WHO clinical stage 
3 or 4, CD4+ count <200 cells/mm3, tuberculosis, and hepatitis B virus co-infection. 
• Significant fibrosis and cirrhosis were associated with increased all-cause mortality during ART.  
• Non-invasive tests for liver fibrosis, particularly low-cost ones such as APRI, should be further 
investigated for routine use in HIV treatment programs in Africa. 
 
Key Words: 
HIV/AIDS, Africa, liver disease, AST-to-platelet ratio index, FIB-4, hepatitis B virus 
 
Introduction: 
Liver disease has become a leading cause of death for HIV-infected patients on antiretroviral 
therapy (ART) in upper-income settings [1,2]. However, in sub-Saharan Africa (SSA), less is 
known regarding the epidemiology of liver disease, largely due to limited availability of 
diagnostic tests for viral hepatitis and for hepatic fibrosis. Although hepatitis B virus (HBV) is 
an endemic cause of liver disease in SSA, few HIV treatment programs have implemented 
routine screening for HBV because of cost [3]. Liver biopsy – the gold standard diagnostic test 
for staging liver disease – is generally unavailable in SSA; it is also invasive and prone to 
sampling error. 
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As an alternative to liver biopsy to stage hepatic fibrosis, non-invasive tests have been recently 
developed and validated. Two indirect blood fibrosis markers, AST-to-platelet ratio index 
(APRI) and FIB-4, as well as an ultrasound-based imaging modality, called transient 
elastography, were included in the 2014 World Health Organization (WHO) guidelines for 
management of hepatitis C virus (HCV) in resource-limited settings [4]. These tests have been 
validated in HCV, HIV-HCV co-infection, HBV, and HIV-HBV co-infection, and have been used 
in published studies of HIV mono-infection in North America, Asia, and Europe [5-9]. Using 
thresholds reported in the WHO guidelines, the accuracy of APRI and FIB-4 ranges from 40-
90%, depending on the population and the threshold selected. To date these tests have not 
been widely investigated in SSA, particularly in relationship to patient outcomes. In a large 
cohort of HIV-infected Zambian adults, we used the APRI score to estimate the prevalence of 
hepatic fibrosis and cirrhosis. We then investigated the association of APRI at the time of ART 
initiation with subsequent all-cause mortality.  
 
Materials and methods: 
We analyzed routine program data from a well-characterized cohort of HIV-infected adults 
receiving antiretroviral therapy in public-sector facilities in Zambia’s capital Lusaka [10]. We 
included HIV-infected patients who were 16+ years old and initiated ART during 2006-2008 
when both aspartate aminotransferase (AST) and platelet count were used in routine ART 
monitoring. Patients were eligible for ART if they had WHO stage 4 disease, a CD4+ count of 
<200 cells/mm3, or WHO stage 3 disease with a CD4+ count <350 cells/mm3. During the period 
of the study, first-line ART regimens comprised stavudine or zidovudine plus lamivudine with 
either nevirapine or efavirenz. In July 2007, tenofovir became the preferred first-line nucleotide 
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reverse transcriptase inhibitor and stavudine and zidovudine were gradually phased out [11]. 
Patients were excluded from analysis if the AST or platelet count results from the time of ART 
initiation were not available. The remaining patients comprised the analysis cohort. 
 
At our reference laboratory, the upper limit of normal was 38 U/L for AST and 33 U/L for ALT. 
When liver disease was suspected based on physical examination or serum transaminases, 
patients were screened for HBV co-infection using a hepatitis B surface antigen serologic 
assay (HBsAg; Access 2 Analyzer, Beckman Coulter Inc.). Testing for HBV DNA and hepatitis 
B e antigen were not available. As it is rare in Zambia [12], hepatitis C virus was not tested for 
in this cohort. Tuberculosis (TB) co-infection was documented when a patient initiated ART 
during treatment with anti-tuberculosis medications. After initiation of ART, follow-up visits for 
clinical examinations and drug refills took place at 2, 6, and 12 weeks, and then every 3-6 
months, based upon clinical status. All-cause mortality was ascertained by report of a family 
member, clinic staff member, or community health worker. Specific causes of death were not 
available.      
 
To assess liver disease at the time of ART initiation, we calculated each patient’s APRI score 
using its formula as follows: {AST (in U/L)/upper limit of normal} / platelet count (expressed as 
platelets x 109/L) X 100 [5]. In our primary analysis, we dichotomized APRI at ≥1.5, an 
established threshold for significant hepatic fibrosis (Metavir stages F2-F4). We also 
considered APRI ≥2.0, a validated threshold for cirrhosis (Metavir stage F4).  
We compared the characteristics of patients excluded from analysis for missing AST or platelet 
results with those in the analysis cohort using Wilcoxon rank sum tests for continuous 
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variables and Chi square tests for categorical ones. Among patients in the analysis cohort, 
using logistic regression, we modeled possible factors associated with significant fibrosis at 
ART initiation including age, sex, body mass index (BMI), WHO clinical stage, CD4+ count, 
and tuberculosis treatment status. Using Kaplan-Meier analysis and Cox proportional hazards 
regression, we examined the association between significant fibrosis and all-cause mortality 
during ART. Cox models were adjusted for confounders that predicted mortality in prior 
analyses of this cohort as follows: age, sex, WHO clinical stage, BMI, CD4+ count, and ART 
regimen. These analyses were then repeated for cirrhosis (i.e., APRI ≥2.0).  
 
Although HBsAg testing was not routine in the cohort, among tested patients, we explored the 
association between HBV co-infection and APRI score using logistic regression adjusted for 
age, sex, BMI, WHO clinical stage, and CD4+ count. Tuberculosis is a common co-infection in 
our program and its treatment may cause elevated serum transaminases and increased APRI 
scores. In a sensitivity analysis, we repeated models after exclusion of TB patients to 
investigate the robustness of the primary results.  
 
Although the focus of this analysis was on APRI, we also calculated FIB-4 scores using its 
formula as follows: {age (in years)*AST (in U/L)} / {platelet count (109/L)*ALT (in U/L)1/2} [13]. 
We dichotomized FIB-4 at ≥3.25, a validated threshold for significant liver fibrosis. Using the 
kappa statistic, we assessed the level of concordance between APRI and FIB-4 at thresholds 
for significant fibrosis.  
We also investigated APRI thresholds that accurately exclude the presence of significant 
fibrosis (APRI ≤0.5) and cirrhosis (APRI ≤1.0). Using Kaplan-Meier analysis we assessed the 
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association of APRI score below these thresholds with subsequent survival. We used Stata 
version 12 (Statacorp, College Station, Texas) for statistical analysis. The Biomedical 
Research Ethics Committee of University of Zambia School of Medicine (Lusaka, Zambia) and 
the Institutional Review Board of University of North Carolina at Chapel Hill (Chapel Hill, North 
Carolina, USA) approved our use of de-identified program data without patient informed 
consent. 
 
Results:  
From 1 July 2006 to 30 Jun 2008, 27,309 HIV-infected adults initiated ART across 22 public-
sector facilities in Lusaka. After the exclusion of those with missing AST and/or platelet counts 
at baseline, 20,308 (74.3%) patients remained in the analysis cohort. Patients with available 
laboratory results were more likely to be male (40.7% vs. 35.9%), have WHO stage 3 or 4 
disease (65.8% vs. 57.5%), CD4+ count <100 cells/mm3 (34.3% vs. 27.6%), and tuberculosis 
co-infection (15.4% vs. 10.8%) compared to those with missing results (all P<0.001). Within 
the analysis cohort median age was 34 years (interquartile range [IQR], 29-40) and 59% were 
women (Table 1). The median APRI score was 0.35 (IQR, 0.23-0.57). According to APRI score 
1,027 (5.1%) had significant fibrosis (APRI ≥1.5) including 616 (3.0%) had cirrhosis (APRI 
≥2.0) at ART initiation. 
 
In multivariable analysis, men were twice as likely as women to have APRI ≥1.5 (adjusted 
odds ratio [AOR], 1.99; 95% confidence interval [CI], 1.72-2.28). Other factors associated with 
significant fibrosis included BMI <18 (AOR, 1.41; 95% CI, 1.00-1.99), WHO clinical stage 3 or 4 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
(AOR, 1.85; 95% CI, 1.54-2.22), tuberculosis co-infection (AOR, 1.18; 95% CI, 1.00-1.39), and 
CD4+ count <100 cells/mm3 (AOR, 3.44; 95% CI, 2.84-4.18; Table 2).  
 
During a total of 49,058 person-years on ART, 2,238 (11.0%) of patients died for an all-cause 
mortality rate of 45.6 per 1000 person-years. Stratified by APRI score at ART initiation, the 
crude mortality rates per 1000 person-years were 39.3 for APRI <0.5, 49.9 for APRI 0.5-1.0, 
74.9 for APRI 1.0-1.5, 71.1 for APRI 1.5-2.0, and 116.4 for APRI >2.0. In Kaplan-Meier 
analysis, significant fibrosis and cirrhosis were associated with increased mortality (both Log 
Rank P<0.001; Figure 1). When compared to patients with APRI <1.5, those with APRI ≥1.5 
had an increased hazard of death (adjusted hazard ratio [AHR], 1.41; 95% CI, 1.21-1.64), 
adjusted for age, sex, BMI, WHO clinical stage, CD4+ count, and ART regimen (Table 3). 
Those with APRI ≥2.0 also experienced increased mortality (AHR, 1.57; 95% CI, 1.31-1.89) 
compared to those with APRI <2.0. 
 
Within the analysis cohort, only 237 (1.2%) patients were tested for HBsAg. Among that 
subset, 49 (20.7%) were HBsAg-positive, and those with positive tests had four times the odds 
(AOR, 4.15; 95% CI, 1.71-10.04) of significant fibrosis compared with HBsAg-negative 
individuals, adjusted for age, sex, CD4+ count, and tuberculosis co-infection.  
The median FIB-4 score in the cohort was 1.06 (IQR, 0.71-1.64) and 1,315 patients (6.5%) had 
significant fibrosis determined by FIB-4 ≥3.25. At thresholds for significant fibrosis, 96.0% of 
patients were staged concordantly by FIB-4 and APRI (Kappa=0.636; P<0.001; Table 4). 
Similar patient characteristics were associated with FIB-4 ≥3.25 as observed in the APRI 
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analysis. In Cox survival models, patients with FIB-4 ≥3.25 experienced increased all-cause 
mortality during ART (AHR, 1.44; 95% CI, 1.25-1.65). 
 
In a sensitivity analysis that excluded patients with tuberculosis, we observed that the mortality 
hazard ratio for significant fibrosis was similar to that of the primary analysis (data not shown). 
At lower thresholds, patients with APRI ≤0.5 and APRI ≤1.0 experienced reduced mortality in 
Kaplan-Meier analysis (both Log Rank P value <0.001; Figure 1).  
 
Discussion: 
Based on APRI – an easy to calculate marker of liver disease – approximately 5% of HIV-
infected Zambian adults had significant hepatic fibrosis or cirrhosis at ART initiation. These 
patients were at much higher risk for mortality, with increases of up to 50%. This highlights the 
need for liver disease screening at the time of ART initiation, along with targeted interventions 
designed to reduce morbidity and improve survival in HIV care centers in resource-constrained 
settings. 
 
Although non-invasive tests are commonly used to stage liver disease in upper-income 
settings, this analysis is one of the first to investigate APRI and FIB-4 in an HIV treatment 
program in SSA. When the Zambian Ministry of Health scaled up ART, a strong commitment 
was made to laboratory monitoring which allowed us to investigate these markers in more than 
20,000 patients receiving treatment. The large size of the cohort allowed us to identify factors 
associated with significant fibrosis and cirrhosis in our program. These results are likely similar 
to other cohorts in the region. 
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We also note several limitations. APRI and FIB-4 are imperfect surrogates of hepatic fibrosis 
and have not been validated in HIV-infected individuals in SSA. Although they have relatively 
high positive predictive value at thresholds for significant fibrosis and cirrhosis, sensitivity can 
be low [4]. In addition, ascertainment of death was incomplete in our program, and some 
deceased patients were likely misclassified as lost to follow-up. We do not believe this 
outcome misclassification would have altered our results because the likelihood that a death 
was documented was unrelated to APRI score. Lack of data on alcohol and herbal medicine 
use and low rates of HBsAg testing were other limitations to our analysis of fibrosis risk factors. 
HBsAg-tested patients in our cohort were selected population according to clinical and 
laboratory triage; therefore, the strong association we observed between HBsAg-positivity and 
APRI cannot be generalized to all HIV-HBV co-infected individuals in this population. HIV 
infection causes thrombocytopenia; therefore, elevated APRI could have been caused by 
untreated advanced HIV disease and not liver disease. Evidence against this is a meta-
analysis where APRI had similar diagnostic accuracy in HCV patients regardless of HIV status 
[14]. Finally we note that – although TB can cause granulomatous hepatitis [15] – anti-TB 
drugs could have confounded the observed association between APRI and mortality through 
elevation of AST. After exclusion of TB patients in a sensitivity analysis, we observed a similar 
association between elevated APRI and mortality.   
 
Based on the APRI score, approximately 5% of HIV-infected patients in Zambia had significant 
fibrosis, similar to the 3-8% reported in published studies in upper-income settings [6,16,17]. 
FIB-4 results were similar, and we observed substantial agreement between FIB-4 and APRI, 
consistent with another report [17]. However, at thresholds used in our and other studies, the 
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burden of significant fibrosis was underestimated with these markers. Liver disease might be 
more common in SSA compared with upper-income settings due to environmental factors such 
as aflatoxin ingestion and traditional herbal medication [18]. In Uganda and Nigeria 10% and 
17% of HIV-infected adults had significant fibrosis based on transient elastography, a non-
invasive fibrosis test that has greater sensitivity than APRI and FIB-4 [19,20]. Herbal 
medication use was associated with liver stiffness measurements in rural Uganda [18]. 
Together these data suggest that HIV-infected individuals in SSA may have a substantial 
bu den of liver disease and further investigation in this field is necessary [21].  
 
Predictors of significant hepatic fibrosis in our cohort included male sex, BMI <18, and low 
CD4+ count. Men were probably more likely to have fibrosis due to HBV and heavy alcohol 
use, two factors that are more common among men than women in our setting [22]. Along with 
alcohol and HCV, chronic HBV is the leading cause of cirrhosis and hepatocellular cancer 
worldwide. Consistent with our data, 30% of HIV-HBV co-infected patients in a U.S. cohort had 
significant fibrosis, based on the APRI score [16]. Although it is an important risk factor for 
chronic liver disease in upper-income settings, overweight/obesity is uncommon in our HIV 
program, and we did not find BMI >25 to be associated with fibrosis. Low BMI, which was 
associated with elevated APRI, is not an established cause of fibrosis, but it may increase 
fibrosis in the setting of alcoholic liver disease [23]. In settings like ours longitudinal studies are 
needed to better understand the impact of malnutrition on liver disease. Our finding that low 
CD4+ count was associated with fibrosis was consistent with at least one study in the U.S. [16] 
although the mechanism for this is poorly understood.  
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Our data suggest that elevated APRI score is associated with poor outcomes among HIV-
infected individuals in Zambia. While we were unable to ascertain liver end points such as 
hepatocellular carcinoma or hepatic failure, we observed that patients with APRI ≥1.5 
experienced increased all-cause mortality during ART, independent of other mortality risk 
factors. This supports published data from Europe and North America where liver disease has 
become a leading cause of mortality for HIV-infected patients receiving ART [1,2].  
 
Non-invasive hepatic fibrosis tests such as APRI are needed in SSA because biopsy is 
invasive and rarely available outside of large urban hospitals [21]. The APRI score could be 
incorporated into HIV clinical care in resource-constrained settings as it relies on inexpensive 
and readily available blood tests and can be determined in real time by simple calculation, 
similar to the creatinine clearance for renal function. A triage strategy could be developed, 
utilizing both high and low APRI thresholds, to identify patients requiring further investigation or 
treatment. The score may also be useful to monitor patients at high risk for liver disease such 
as those with chronic viral hepatitis or excess alcohol consumption. In conclusion, our findings 
– that 1 in 20 Zambian HIV patients had significant hepatic disease and hepatic disease 
predicts mortality during ART – support the need for future research into the role of non-
invasive fibrosis tests in HIV treatment programs in SSA. 
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Table 1. Demographic, clinical, and treatment characteristics of the cohort, by the 
degree of hepatic fibrosis based on the AST-to-platelet ratio index 
 APRI <1.5  
No significant fibrosis 
(n=19,281) 
APRI ≥1.5  
Significant fibrosis 
(n=1,027) 
P 
Age, years 34 (29-40) 34 (30-39) <0.001
Male sex 7,771 (40) 621 (59) <0.001
WHO clinical stage 
     1 or 2 
     3 or 4 
 
6,734 (35) 
12,441 (65) 
 
180 (18) 
846 (82) 
 
<0.001
Body mass index 
     >25 
     18-25 
     <18 
 
1,679 (9) 
11,868 (63) 
5,201 (28) 
 
40 (4)  
551 (56) 
402 (40) 
 
<0.001
 
Tuberculosis 2,899 (15) 238 (23) <0.001
CD4+ count, cells/mm3 
      >200 
      100-200 
      <100 
 
6,326 (34) 
6,024 (33) 
6,089 (33) 
 
146 (15) 
260 (27) 
568 (58) 
 
 
<0.001
ART regimen 
     NRTI 
        D4T+3TC 
        AZT+3TC 
        TDF+XTC 
     NNRTI 
        NVP 
        EFV 
 
 
6,962 (36) 
5,702 (30) 
6,490 (34) 
 
13,528 (70) 
5,753 (30) 
 
 
447 (44) 
214 (21) 
360 (35) 
 
554 (54) 
473 (46) 
 
 
<0.001
 
 
 
<0.001
 
All values are median (IQR) or number (%). 
Abbreviations: APRI, AST-to-platelet ratio index; AST, aspartate aminotransferase; 
WHO, World Health Organization; NRTI, nucleotide reverse transcriptase inhibitor; 
NNRTI, non-nucleotide reverse transcriptase inhibitor; D4T, stavudine; 3TC, 
lamivudine; XTC, either lamivudine or emtricitabine; AZT, zidovudine; TDF, tenofovir; 
NVP, nevirapine; EFV, efavirenz; ART, antiretroviral therapy 
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Table 2. Factors associated with having either significant hepatic fibrosis or 
cirrhosis, based on the AST-to-platelet ratio index, at ART initiation in Zambia  
APRI ≥1.5 (Significant fibrosis) 
Crude 
OR (95% CI) 
Adjusted 
OR (95% CI) 
   Age, per 10-year increase 1.03 (0.97-1.10) 0.95 (0.88-1.03) 
   Male sex 2.22 (1.96-2.52) 1.98 (1.72-2.28) 
   BMI 
        >25 
        18-25 
        <18 
 
Reference 
1.93 (1.40-2.66) 
3.21 (2.32-4.44) 
 
Reference 
1.25 (0.90-1.74) 
1.41 (1.00-1.99) 
   WHO clinical stage 3 or 4 2.50 (2.12-2.93) 1.82 (1.52-2.18) 
   Tuberculosis 1.71 (1.48-1.99) 1.20 (1.02-1.41) 
   CD4+ count, cells/mm3 
        >200 
        100-200 
        <100 
 
Reference 
1.87 (1.52-2.29) 
4.03 (3.36-4.85) 
 
Reference 
1.84 (1.49-2.27) 
3.44 (2.84-4.18) 
APRI ≥2.0 (Cirrhosis) 
   Age, per 10-year increase 0.98 (0.89-1.07) 0.89 (0.81-0.99) 
   Male sex 2.22 (1.89-2.61) 2.04 (1.70-2.43) 
   BMI  
        >25 
        18-25 
        <18 
 
Reference 
1.95 (1.27-2.98) 
3.67 (2.39-5.63) 
 
Reference 
1.26 (0.81-1.97) 
1.59 (1.01-2.50) 
   WHO clinical stage 3 or 4 2.50 (2.03-3.07) 1.76 (1.39-2.22) 
   Tuberculosis 1.82 (1.51-2.19) 1.26 (1.03-1.55) 
   CD4+ count, cells/mm3 
        >200 
        100-200 
        <100 
 
Reference 
1.91 (1.46-2.50) 
4.28 (3.37-5.45) 
 
Reference 
1.87 (1.42-2.46) 
3.47 (2.70-4.46) 
Abbreviations: AST, aspartate aminotransferase; ART, antiretroviral therapy; 
OR, odds ratio; BMI, body mass index; WHO, World Health Organization 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
Table 3. Association of hepatic fibrosis at ART initiation with all-cause mortality 
among HIV-infected Zambian adults 
 Crude 
AHR (95% CI) 
Adjusted 
AHR (95% CI) 
Hepatic fibrosis level 
     APRI <1.5 (No significant fibrosis) 
     APRI ≥1.5 (Significant fibrosis) 
 
Reference 
2.08 (1.80-2.40) 
 
Reference 
1.41 (1.21-1.64) 
Age, per 10-year increase 1.11 (1.06-1.16) 1.10 (1.05-1.16) 
Male sex 1.46 (1.34-1.58) 1.28 (1.17-1.40) 
WHO clinical stage 3 or 4 2.29 (2.06-2.54) 1.61 (1.44-1.81) 
Body mass index 
     >25 
     18-25 
     <18 
 
Reference 
1.67 (1.35-2.06) 
3.75 (3.03-4.64) 
 
Reference 
1.30 (1.05-1.62) 
2.20 (1.76-2.74) 
CD4+ count, cells/mm3 
     >200 
     100-200 
     <100 
 
Reference 
1.36 (1.20-1.54) 
2.66 (2.39-2.97) 
 
Reference 
1.30 (1.14-1.47) 
2.04 (1.81-2.29) 
ART regimen  
   NRTIs 
        D4T+3TC 
        AZT+3TC 
        TDF+XTC 
   NNRTI 
        NVP 
        EFV 
 
 
Reference 
0.43 (0.39-0.49) 
0.77 (0.70-0.85) 
 
Reference 
1.16 (1.06-1.26) 
 
 
Reference 
0.51 (0.45-0.57) 
0.82 (0.74-0.91) 
 
Reference 
0.85 (0.77-0.94) 
Abbreviations: ART, antiretroviral therapy; WHO, world health organization; AHR, 
adjusted hazard ratio; NRTI, nucleotide reverse transcriptase inhibitor; NNRTI, non-
nucleotide reverse transcriptase inhibitor; D4T, stavudine; 3TC, lamivudine; XTC, 
either lamivudine or emtricitabine; AZT, zidovudine; TDF, tenofovir; NVP, nevirapine; 
EFV, efavirenz 
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Table 4. Percentage agreement between APRI and FIB-4 
scores among HIV-infected Zambian adults initiating ART 
 APRI, n (%) of patients 
FIB-4 ≤1.5 >1.5 
≤3.25 18,735 (92.2) 258 (1.3) 
>3.25 546 (2.7) 769 (3.8) 
Abbreviations: APRI, AST-to-platelet ratio index; ART, 
antiretroviral therapy 
 
 
 
